



## NEWS RELEASE

**For Further Information Contact:**

Roy Wolvin  
Nymox Pharmaceutical Corporation  
1-800-93NYMOX  
www.nymox.com

**For Immediate Release:**

### **Nymox Announces \$13 Million Equity Financing**

HASBROUCK HEIGHTS, NJ (November 29, 2006) Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today that the Company has secured new commitment for \$13 million in private equity financing. The funds will be used for general corporate purposes. The private placement of common stock is with institutional investors who have participated in previous successful financings for the company, and is priced at a 3% discount to the market price. There are no warrants with the placement and no restrictions on other corporate financing.

Nymox's CEO, Paul Averbach, said, "This financing allows Nymox to continue to advance our products in development to market while maintaining our very low burn rate, with minimal dilution to our shareholders. The company has no long term debt."

Nymox Pharmaceutical Corporation is a biotechnology company engaged in the research and development of therapeutics and diagnostics, with a particular emphasis on products targeted for the unmet needs of the aging population. Currently Nymox has three products on the market, and a healthy pipeline of drug and diagnostic products. The Company also has several hundred patents and patent applications. The Company is developing NX-1207, a drug for benign prostatic hyperplasia (BPH). The Company recently announced positive results from a large U.S. multi-center Completed Phase 2 study of NX-1207. Nymox has a number of drugs in development for *E. coli* infection, Alzheimer's disease, oncology, and infectious disease. The Company markets NicAlert™ and TobacAlert™ tests for measuring tobacco product exposure, and AlzheimAlert™, a test to aid in the diagnosis of Alzheimer's disease.

More information about Nymox is available at [www.nymox.com](http://www.nymox.com), email: [info@nymox.com](mailto:info@nymox.com), or 800-936-9669.

*This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's current expectations. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.*

###